```
=> s l1 full
FULL SEARCH INITIATED 13:08:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       15 TO ITERATE

100.0% PROCESSED       15 ITERATIONS                                 8 ANSWERS
SEARCH TIME: 00.00.01

L2             8 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     172.94

FILE 'CAPLUS' ENTERED AT 13:08:19 ON 07 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 7 Jul 2007  VOL 147 ISS 3
FILE LAST UPDATED: 6 Jul 2007  (20070706/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3             1 L2

=> d l3 bib abs hitstr

L3   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2006:1323526  CAPLUS
DN   146:229554
TI   A base-stable dithiomethyl linker for solid-phase synthesis of
     oligonucleotides
AU   Semenyuk, Andrey; Kwiatkowski, Marek
CS   Department of Genetics and Pathology, Uppsala University, Uppsala, 75185,
     Swed.
SO   Tetrahedron Letters (2006), Volume Date 2007, 48(3), 469-472
     CODEN: TELEAY; ISSN: 0040-4039
PB   Elsevier Ltd.
DT   Journal
LA   English
OS   CASREACT 146:229554
AB   A novel linkage, useful for the synthesis of oligonucleotides is
     described.  The linking function is compatible with all conditions used
     for oligonucleotide synthesis, orthogonal to all other protecting groups,
     but regenerates 3'-OH rapidly upon mild reduction under aqueous conditions.
This
```

method is employed in the removal of depurinated fragments during the synthesis of oligonucleotides.

IT 923928-57-8P 923928-58-9P 923928-59-0P
923928-60-3P 923928-61-4P 923928-62-5P
923928-63-6P 923928-64-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(base-stable dithiomethyl linker for solid-phase synthesis of oligonucleotides)

RN 923928-57-8 CAPLUS
CN Thymidine, 3'-O-[[(6-hydroxyhexyl)dithio]methyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 923928-58-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 923928-59-0 CAPLUS
CN Thymidine, 3'-O-[[(3-hydroxy-1,1-dimethylpropyl)dithio]methyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 923928-60-3 CAPLUS
CN Thymidine, 3'-O-[[[3-[[[(5-hydroxypentyl)amino]carbonyl]oxy]-1,1-dimethylpropyl]dithio]methyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 923928-61-4 CAPLUS
CN Thymidine, 3'-O-[[(6-hydroxy-1,1-dimethylhexyl)dithio]methyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 923928-62-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 923928-63-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 923928-64-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

```
=>
=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         6.68     179.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -0.78      -0.78

FILE 'BIOSIS' ENTERED AT 13:10:03 ON 07 JUL 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 13:10:03 ON 07 JUL 2007

FILE 'CAPLUS' ENTERED AT 13:10:03 ON 07 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:10:03 ON 07 JUL 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 13:10:03 ON 07 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s dithiomethyl? and nucleobase
L4            0 DITHIOMETHYL? AND NUCLEOBASE

=> s dithiomethyl? and nucleoside
L5            6 DITHIOMETHYL? AND NUCLEOSIDE

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6            6 DUP REM L5 (0 DUPLICATES REMOVED)

=> d l6 bib abs 1-6

L6   ANSWER 1 OF 6  USPATFULL on STN
AN     2007:30168  USPATFULL
TI     Methods of producing and sequencing modified polynucleotides
IN     Smith, Douglas R., Gloucester, MA, UNITED STATES
       McKernan, Kevin J., Marblehead, MA, UNITED STATES
PI     US 2007026438       A1  20070201
AI     US 2006-476423      A1  20060628 (11)
PRAI   US 2005-694783P     20050628 (60)
DT     Utility
FS     APPLICATION
LREP   HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
       9133, CONCORD, MA, 01742-9133, US
CLMN   Number of Claims: 53
ECL    Exemplary Claim: 1
DRWN   5 Drawing Page(s)
LN.CNT 1482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention encompasses methods for producing a modified
       polynucleotide sequence that comprises a (e.g., one or more)
       phosphorothiolate linkage, methods for determining a polynucleotide
       sequence comprising a (e.g., one or more) phosphorothiolate linkage, and
       methods for separating forward and reverse extension products that
```

comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 6 USPATFULL on STN
AN 2007:172973 USPATFULL
TI Compounds and methods to inhibit or augment an inflammatory response
IN Grainger, David J., Cambridge, UNITED KINGDOM
Tatalick, Lauren Marie, Redmond, WA, UNITED STATES
PA Cambridge University Technical Services Ltd., Cambridge, UNITED KINGDOM (non-U.S. corporation)
PI US 7238711 B1 20070703
AI US 1999-452406 19991201 (9)
RLI Continuation-in-part of Ser. No. US 1999-271192, filed on 17 Mar 1999, ABANDONED
DT Utility
FS GRANTED
EXNAM Primary Examiner: Hui, San-Ming
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 73 Drawing Figure(s); 75 Drawing Page(s)
LN.CNT 9658
AB Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.

L6 ANSWER 3 OF 6 USPATFULL on STN
AN 2006:150972 USPATFULL
TI Anti-integrin immunoconjugates, methods and uses
IN Chen, Qiming, Collegeville, PA, UNITED STATES
Trikha, Mohit, San Mateo, CA, UNITED STATES
Lutz, Robert J., Wayland, MA, UNITED STATES
Steeves, Rita M., Stoneham, MA, UNITED STATES
Amphlett, Godfrey, Cambridge, MA, UNITED STATES
PI US 2006127407 A1 20060615
AI US 2005-290249 A1 20051130 (11)
PRAI US 2004-634445P 20041209 (60)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 6 USPATFULL on STN
AN 2006:86115 USPATFULL
TI Compounds and methods to inhibit or augment an inflammatory response
IN Grainger, David J., Cambridge, UNITED KINGDOM
Tatalick, Lauren Marie, Redmond, WA, UNITED STATES
Kanaly, Suzanne T., Seattle, WA, UNITED STATES
PA Cambridge University Technical Services Ltd. (non-U.S. corporation)
PI US 2006073114 A1 20060406
AI US 2002-241375 A1 20020911 (10)
RLI Continuation of Ser. No. US 1998-150813, filed on 11 Sep 1998, PENDING
Continuation-in-part of Ser. No. US 1997-927939, filed on 11 Sep 1997, GRANTED, Pat. No. US 6989435
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, 1600 TCF TOWER, 121 SOUTH EIGHT STREET, MINNEAPOLIS, MN, 55402, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1-51
DRWN 23 Drawing Page(s)
LN.CNT 7392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 6 USPATFULL on STN
AN 2006:162126 USPATFULL
TI Compounds and methods to inhibit or augment an inflammatory response
IN Grainger, David J., Duxford, UNITED KINGDOM
Tatalick, Lauren Marie, Redmond, WA, UNITED STATES
Kanaly, Suzanne T., Seattle, WA, UNITED STATES
PA Cambridge University Technical Services, Ltd., Cambridge, UNITED KINGDOM (non-U.S. corporation)
PI US 7067117 B1 20060627
AI US 1998-150813 19980911 (9)
RLI Continuation-in-part of Ser. No. US 1997-927939, filed on 11 Sep 1997, PENDING
DT Utility
FS GRANTED
EXNAM Primary Examiner: Murphy, Joseph
LREP Schwegman, Lundberg, Woessner & Kluth, P.A.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 7861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 6 USPATFULL on STN
AN 2002:106274 USPATFULL
TI 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections
IN Watanabe, Kyoichi A., Stone Mountain, GA, UNITED STATES
Pai, S. Balakrishna, Chamblee, GA, UNITED STATES
PI US 2002055483 A1 20020509
US 7094770 B2 20060822
AI US 2001-834596 A1 20010413 (9)
PRAI US 2000-197068P 20000413 (60)

US 2000-202663P 20000508 (60)
DT Utility
FS APPLICATION
LREP TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET , NE, ATLANTA, GA, 30308-2216
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]- [IV] below and mixtures of two or more thereof: ##STR1##

wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.